🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

BMO cuts Verve Therapeutics shares target, cites lead candidate 'VERVE-101'

EditorEmilio Ghigini
Published 04/03/2024, 08:08 AM

On Wednesday, BMO Capital Markets adjusted its price target on Verve Therapeutics (NASDAQ:VERV) shares. The firm reduced the price target to $30 from the previous $56, while keeping an Outperform rating.

The decision to lower the price target follows recent developments regarding Verve Therapeutics' lead candidate, VERVE-101. The management has decided to shift focus to another drug candidate, VERVE-102, after observing a grade 3 adverse event (AE) in patients receiving doses under 0.45 milligrams per kilogram of VERVE-101.

Despite the setback with VERVE-101, BMO Capital notes that gene editing therapy has shown promise, with a significant and durable reduction in low-density lipoprotein cholesterol (LDL-C) observed in patients. The treatment achieved up to 73% reduction in LDL-C levels over a period exceeding 270 days. Additionally, it is highlighted that no cardiovascular or myocardial infarction events were reported in the five new patients treated.

The competitive arena for LDL-C reduction treatments is acknowledged as a challenge for VERVE-101's path forward. However, BMO Capital anticipates that VERVE-102's broad therapeutic window could address the safety concerns raised by VERVE-101, although it also recognizes that the recent news adds to the uncertainty surrounding gene editing therapies.

InvestingPro Insights

Following the recent developments at Verve Therapeutics and the adjustment of the stock's price target by BMO Capital Markets, a look at the real-time data from InvestingPro provides additional context for investors. With a market capitalization of approximately $695.71 million, Verve Therapeutics holds a substantial cash position that exceeds its debt, according to InvestingPro Tips. This could be a reassuring sign for investors looking for financial stability in their investments. Additionally, the stock's price-to-book ratio stands at 1.16 as of the last twelve months ending Q4 2023, suggesting that the company's assets are valued reasonably in the market.

InvestingPro Tips also highlight that the stock is currently in oversold territory as per the Relative Strength Index (RSI), which may signal a potential rebound opportunity for investors. However, it's important to note that analysts do not expect the company to be profitable this year, and the stock has experienced significant volatility with a 48.93% decline over the last month. These factors should be carefully weighed by potential investors.

For those interested in a deeper dive into Verve Therapeutics' financials and stock performance, InvestingPro offers additional tips and metrics. Using the promo code PRONEWS24, investors can get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, gaining access to a wealth of expert analysis and data to inform their investment decisions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.